Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib vs Sunitinib in Advanced Renal Cell Carcinoma
NCT02072031Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in renal cell carcinoma (RCC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression Free Survival up to 36 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02072031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072031.